Press Releases Q BioMed Inc.

Equities

QBIO

US74736N1054

Market Closed - OTC Markets Other stock markets 11:59:07 09/05/2024 pm IST			5-day change	1st Jan Change
0.0006 ^USD	+20.00%		+20.00%	+50.00%

2023	Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023	CI
2023	Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Q BioMed Inc. Provides Update to Shareholders	23/23/23	PR
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe	17/23/17	AQ
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe	14/23/14	PR
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office	13/23/13	AQ
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office	10/23/10	PR
Q BIOMED INC. : Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	19/22/19	AQ
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	04/22/04	AQ
Q BIOMED PROVIDES SHAREHOLDER UPDATE	11/22/11	PR
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER	27/22/27	PR
Q BioMed Inc. Provides Update to Shareholders	29/22/29	PR
Q BioMed : Quarterly Report for Quarter Ending May 31, 2022 (Form 10-Q)	29/22/29	PU
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	29/22/29	AQ
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer	26/22/26	PR
Q BIOMED INC. : Unregistered Sale of Equity Securities (form 8-K)	14/22/14	AQ
Q BioMed Outlines Strategy and Value Proposition in Multi-Billion Dollar Markets	06/22/06	PR
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)	15/22/15	AQ
Q BioMed announces publication of research showing augmented efficacy of its drug candidate Uttroside-B against liver cancer	16/22/16	PR
Q BioMed Announces Initial $500k Order of Strontium89 to Chinese Market	07/22/07	PR
Q BIOMED INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	01/22/01	AQ
Q BioMed Outlines Strategic Direction for 2022	14/22/14	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Q BioMed Inc.

Equities

QBIO

US74736N1054

Press Releases

Filters